NeuroTherapia Reports Promising Phase 2a Alzheimer’s Data
CLEVELAND, Ohio, July 13, 2026 NeuroTherapia, Inc. has announced encouraging findings from its Phase 2a clinical trial evaluating NTRX-07,...
Clinical Trials for New Therapy
PharmatrophiX Reports Positive LM11A-31 Alzheimer’s Results
MENLO PARK, California, July 13, 2026 PharmatrophiX, in collaboration with Indiana University School of Medicine, has presented encouraging new...
IN8bio Publishes Positive Phase 1 GBM Data
NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...
AB Science Prioritizes AML and ALS Programs
PARIS, July 10, 2026 AB Science announced a major strategic update to its clinical development pipeline, confirming that it...
Vaccinex Showcases Pepinemab Biomarker Results
ROCHESTER, N.Y., July 8, 2026 Vaccinex announced that it will present new biomarker findings from its Phase 1b/2 SIGNAL-AD...
MAIA Biotechnology Reports Positive Phase 2 THIO-101 Data in Third-Line NSCLC
CHICAGO, July 8, 2026 MAIA Biotechnology announced encouraging interim efficacy results from Part C of its Phase 2 THIO-101...
Opus Genetics Provides BEST1 Phase 1/2 Trial Timeline for OPGx-BEST1 Data
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
INmune Bio Reports Positive Phase 2 XPro Data
INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...
CervoMed Completes Phase 2 Enrollment of Neflamapimod in nfvPPA
CervoMed, BOSTON, July 9, 2026 CervoMed Inc. has announced the successful completion of enrollment in its Phase 2a clinical...
Avance Clinical Unveils Asia Growth Strategy at BIO Asia–Taiwan
TAIPEI, Taiwan | July 10, 2026 Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO), has announced its participation...